Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 16 h ago

GH Research PLC: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. amended its Schedule 13G filing on GH Research PLC, disclosing a change in its passive stake in the clinical-stage biotech. The SEC filing, accession number 0000921895-26-003180, was submitted under the fund's filing agent. The amendment updates the fund's previously reported beneficial ownership position in the company. Schedule 13G filings are required of investors holding more than 5% of a class of registered equity securities who do not seek control of the issuer. Investors will watch for further 13G or 13D amendments to gauge whether the fund is accumulating or trimming its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

GH Research PLC, BIOTECHNOLOGY VALUE FUND L P